Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-01-19

Clinical Trial Update: Safety and Efficacy of AGN201781 in Neuropathic Pain [Phase 2]

View source ↗

Summary

Allergan's AGN201781 in neuralgia (neuropathic pain) underwent a Phase 2 trial that was terminated. Results from the study were posted on 2012-01-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AGN201781

Snippet

Sponsor: Allergan | Conditions: Neuralgia | Phase 2 | Status: TERMINATED | Results posted: 2012-01-19